Share to:

 

Ergotamin

Ergotamin
Nama sistematis (IUPAC)
(6aR,9R)-N-((2R,5S,10aS,10bS)-5-Benzyl-10b-hydroxy-2-methyl-3,6-dioxooctahydro-2H-oxazolo[3,2-a]pyrrolo[2,1-c]pyrazin-2-yl)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Data klinis
Nama dagang Cafergot (with caffeine), Ergomar, others
AHFS/Drugs.com monograph
Kat. kehamilan X(US)
Status hukum Harus dengan resep dokter (S4) (AU) Schedule VI (CA) POM (UK) -only (US)
Rute Oral
Data farmakokinetik
Bioavailabilitas Intravenous: 100%,[1]
Intramuscular: 47%,[2]
Oral: <1%[3] (Enhanced by co-administration of caffeine[1])
Metabolisme Hepatic[2]
Waktu paruh 2 hours[2]
Ekskresi 90% biliary[2]
Pengenal
Nomor CAS 113-15-5 YaY
Kode ATC N02CA02
PubChem CID 8223
Ligan IUPHAR 149
DrugBank DB00696
ChemSpider 7930 YaY
UNII PR834Q503T YaY
KEGG D07906 YaY
ChEBI CHEBI:64318 N
ChEMBL CHEMBL442 YaY
Sinonim 2'-Methyl-5'α-benzyl-12'-hydroxy-3',6',18-trioxoergotaman; 9,10α-Dihydro-12'-hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione
Data kimia
Rumus C33H35N5O5 
  • InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 YaY
    Key:XCGSFFUVFURLIX-VFGNJEKYSA-N YaY

Ergotamin adalah obat yang digunakan untuk meredakan atau mencegah migrain. Obat ergotamin biasanya dapat ditemukan dalam produk obat yang dikombinasikan dengan kafein. Obat ergotamin merupakan vasokonstriktor agonis adrenergik selektif alfa-1.[4][5]

Referensi

  1. ^ a b Sanders SW, Haering N, Mosberg H, Jaeger H (1986). "Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing". European Journal of Clinical Pharmacology. 30 (3): 331–334. doi:10.1007/BF00541538. PMID 3732370. 
  2. ^ a b c d Tfelt-Hansen P, Johnson ES (1993). "Ergotamine". Dalam Olesen J, Tfelt-Hansen P, Welch KM. The Headaches. New York: Raven Press. hlm. 313–22. 
  3. ^ Ibraheem JJ, Paalzow L, Tfelt-Hansen P (December 1983). "Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers". British Journal of Clinical Pharmacology. 16 (6): 695–699. doi:10.1111/j.1365-2125.1983.tb02243.x. PMC 1428366alt=Dapat diakses gratis. PMID 6419759. 
  4. ^ "Ergotamine-Caffeine Oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD". www.webmd.com (dalam bahasa Inggris). Diakses tanggal 2023-06-20. 
  5. ^ "Ergotamine". go.drugbank.com. Diakses tanggal 2023-06-20. 
Kembali kehalaman sebelumnya